NUSNU SKIN ENTERPRISES, INC.
Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Revenue
- $1.5B
- 14% YoY
- Operating margin
- 4.4%
- 151% YoY
- EBITDA
- $118M
- 244% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.5×
- $64M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired50% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear40% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.2B | $2.0B | $1.7B | $1.5B | 14% |
| Operating income | $234M | $111M | $48M | −$152M | $66M | 143% |
| Net income | $147M | $105M | $9M | −$147M | $160M | 209% |
| Operating cash flow | $142M | $108M | $119M | $112M | $80M | 28% |
| Capex | $69M | $59M | $58M | $42M | $34M | 18% |
| Stock-based comp | $23M | $12M | $16M | $15M | $24M | 63% |
| Buybacks | $80M | $70M | $13M | $0 | $20M | |
| Dividends | $76M | $77M | $78M | $12M | $12M | 0.8% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.